Memo Therapeutics

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

Memo Therapeutics company profile

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Business identity

Contact email
[email protected]
Phone number
+41 44-515-91-40
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
7
Total equity funding
$97.4M
Last funding
Series C / $22M / 2024-05-07
Last equity funding
Series C / $22M
Investors
18
Lead investors
4
Founders
1
Articles
77

Founders and investors

Founders

Christoph Esslinger

Lead investors

Federal Office of Public Health (FOPH) SwitzerlandPureos BioventuresredalpineSwisscanto Private Equity

Investors

Kurma PartnersSchroders CapitalVerve VenturesYsios CapitalZürcher Kantonal Bank